The Guangdong - Hong Kong - Macao Greater Bay Area Biomedicine and Life Health Industry Summit Forum and Shenzhen-Hong Kong Biomedical, Life Sciences and Medical Device Development Opportunities and Roadmap Seminar with the theme of “INVEST IN SHENZHEN, BUILD A WINNING FUTURE” was held at Hong Kong Polytechnic University on the afternoon of July 18. The event was jointly organized by Invest Shenzhen, Yantian District People’s Government and the Hong Kong Polytechnic University, with a focus on the cooperative development of the biomedicine and life health industry in the Guangdong - Hong Kong - Macao Greater Bay Area. The event highlighted the advantages of resources, policies and complementary industries of Guangdong, Hong Kong and Macao and aimed to increase the depth of industrial cooperation, accelerate the integration of industrial chains, and promote the integration of Guangdong - Hong Kong - Macao Greater Bay Area within the international community to achieve success on all fronts. The event was supported by the Development and Reform Commission of Shenzhen Municipality, China Council for the Promotion of International Trade - Shenzhen, Shenzhen Pharmaceutical Industry Association, Shenzhen Dabaihui Property Development Co., Ltd. and Meinian Onehealth Healthcare Holdings Co., Ltd..
Mr. Zhang Zongming, Deputy Inspector of the Education and Technology Department of the Liaison Office of the Central People's Government in the Hong Kong Special Administrative Region, attended the event and delivered a speech in which he mentioned the following points: the construction of the Guangdong - Hong Kong - Macao Greater Bay Area was included in Xi Jinping's Report at 19th CPC National Congress as a national development strategy, which would help Hong Kong and Macao to join in the overall national development and accelerate comprehensive and mutually-beneficial cooperation with the mainland; the "One Country, Two Systems" was the biggest advantage in the development of the Greater Bay Area and it is necessary to give full play to the overlapping advantages of various systems, and promote the innovation and development of the Greater Bay Area by fanning out from a specific point; formation of a globally competitive bay area would establish a fulcrum for growth; the biomedicine and life health industry is the most dynamic emerging industry in the world today, and also a key development area in Hong Kong; the relevant talent pools are abundant, as there are five of the World's Top 100 Universities located in Hong Kong.
Ms. Zhang Feimeng, Deputy Director General of Invest Shenzhen, offered a sincere welcome to the leaders and guests attending the event. She said the development opportunities provided by the Guangdong - Hong Kong - Macao Greater Bay Area and the important position of the biomedicine and life health industry in leading regional development have become increasingly clear. As Shenzhen was included in the first batch of national bio-industry bases to be set up, its biomedicine and life health industry exceeded the RMB 200 billion mark in terms of scale in 2017. The area boasts the world’s No. 1 next generation of sequencing capabilities and has the only national gene bank in China. Hong Kong has strong research and development capabilities, and many cutting-edge scientific research technologies are in urgent need of transformation, while Macao is a leader in traditional Chinese medicine research. Guangdong Province has strong transformative and application capabilities in biotechnology, so the three regions should work together to strengthen cooperation and promote high-end factor aggregation, she said.
Mr. Shi Weigan, Executive Deputy Chief of Yantian District People’s Government, delivered welcome remarks and said as Shenzhen was the first national innovation city and national independent innovation demonstration zone, Yantian District Committee and Yantian District Government have attached great importance to implementing the innovation-driven development strategy and making full use of the beautiful ecological environment and advantageous industrial base of Yantian District. The government will focus on developing the biomedicine and life health industry, and open up a new road to industrial upgrades with leading high-end industrial agglomeration and intelligent development, he said. With the aim of building Shenzhen Dabaihui Life and Health Industrial Park, the area has built the largest industrial park with the most complete support facilities and has the most professional features in the history of Yantian District, said Shi. The area comprehensively assists enterprises to invest in research and development, attact talents, secure funding and protect intellectual property.
Mr. Wei Bingjiang, Vice President of Hong Kong Polytechnic University, gave an overview of the university and explained that it is a famous institution of higher learning in Asia and ranked No.95 in the world. The school has a solid scientific research culture and attaches great importance to research into applied technology. This year, Hong Kong Polytechnic University sealed an MOU for cooperation with Guangzhou’s Sun Yat-Sen University, Shenzhen University, Macau University of Science and Technology and the State University of New York at Buffalo to jointly build the first biotechnology and translational medicine collaborative research platform in the Guangdong-Hong Kong-Macao Greater Bay Area.
At the meeting, Dr. Zeng Lu, Director of the Guangdong Academy of Science and Technology Service gave a keynote speech on the construction of the technology roadmap for the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area. Qin Wei of the Development and Reform Commission of Shenzhen Municipality also introduced the development of the city’s bio-industry and gave an overview of relevant industrial policies.
The event was also attended by representatives of more than 100 industry giants and well-known investment institutions, including Mr. Liang Jinsong, Chairman and Chief Executive Officer of Hong Kong Nan Fung Group, Mr. Wang Yonghui, Chairman of Xiangxue Pharmaceutical, Mr. Liu Yaonan, Chairman and Chief Executive Officer of Athenex, Dr. Yang Hongyi, General Manager of Athenex, and Dr. William Zuo, President of Polymed Therapeutics. Executives and officials from the following companies and institutions were also in attendance including the University of Hong Kong, Macau University of Science and Technology, GE Medical Systems Information Technologies, Porton Pharma Solutions Ltd., Shanghai Pharma, Fortune Pharmacal, JPMorgan Chase, Credit Suisse Group, and the Dabaihui Group. The topics discussed included bio-industry policy and interpretation of government-led initiatives, biomedicine and biotechnology cooperation opportunities, medical devices, life sciences and hospital collaborative opportunities in the Guangdong - Hong Kong - Macao Greater Bay Area. These discussions focused on promoting effective exchanges and cooperation between the parties and jointly nurture synergies in the development of the biomedicine and life health industry in the Guangdong-Hong Kong - Macao Greater Bay Area.
On July 19-20, Invest Shenzhen visited leading industrial companies such as Bupa Group, Gübelin Group and Fortune Pharmacal to discuss cooperation matters in connection to investment in Shenzhen.